# Program 1 Architecture Review Track Phase D5 - Prohibited Write-Back and Mutation Paths

Status: documentation-only prohibited mutation register.

| Prohibited target | Mutation risk | Current decision | Future review dependency |
| --- | --- | --- | --- |
| Program 1 -> EHR/EMR | Clinical system write-back | Prohibited | Clinical safety, security, and implementation authorization |
| Program 1 -> production database | Production data mutation | Prohibited | Production governance and implementation authorization |
| Program 1 -> appointment system | Scheduling mutation | Prohibited | Appointment governance review |
| Program 1 -> patient portal | Patient-facing output | Prohibited | Patient communication and privacy/legal review |
| Program 1 -> staff workflow system | Workflow enforcement | Prohibited | Workflow governance review |
| Program 1 -> patient messaging system | Patient communication | Prohibited | Patient communication governance |
| Program 1 -> audit event store | Runtime audit capture | Prohibited | Audit/security architecture review |
| Program 1 -> authorization state | Runtime access grant or denial | Prohibited | Security architecture review |
| Program 1 -> approval/override state | Approval or override capability | Prohibited | Governance authorization; no automatic approval |
| Program 1 -> clinical note | Clinical write-path | Prohibited | Clinical accountability review |
| Program 1 -> diagnosis | Diagnosis writing | Prohibited | Clinical safety review |
| Program 1 -> treatment plan | Treatment execution | Prohibited | Clinical safety review |
| Program 1 -> task assignment | Task engine or workflow activation | Prohibited | Workflow governance review |
| Program 1 -> outcome evidence record | Outcome Evidence activation | Prohibited | Outcome governance review |

## Decision

No write-back or mutation path is allowed by Phase D. Program 1 remains non-mutating, non-runtime, synthetic-only, and pre-implementation.
